Baron, Ralf
Ferriero, Donna M.
Frisoni, Giovanni B.
Bettegowda, Chetan
Gokaslan, Ziya L.
Kessler, John A.
Vezzani, Annamaria
Waxman, Stephen G.
Jarius, Sven
Wildemann, Brigitte
Weller, Michael
Article History
First Online: 27 October 2015
Competing interests
: R.B. has received research support from Pfizer, Genzyme, Grünenthal and Mundipharma. He is a member of the IMI Europain collaboration, which has the following industry members: Astra Zeneca, Pfizer, Esteve, UCB-Pharma, Sanofi Aventis, Grünenthal, Eli Lilly and Boehringer Ingelheim. He has received speaking fees from Pfizer, Genzyme, Grünenthal, Mundipharma, Sanofi Pasteur, Medtronic, Eisai, Lilly, Boehringer Ingelheim, Astellas, Desitin, Teva Pharma, Bayer Schering, MSD and bioCSL. He has consulted for Pfizer, Genzyme, Grünenthal, Mundipharma, Allergan, Sanofi Pasteur, Medtronic, Eisai, Lilly, Boehringer Ingelheim, Astellas, Novartis, Bristol–Myers Squibb, Biogen Idec, Astra Zeneca, Merck, Abbvie, Daiichi Sankyo, Glenmark Pharmaceuticals and bioCSL. B.W. receives research support from Merck Serono. M.W. has received research grants from Acceleron, Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck & Co, Novocure, PIQUR and Roche, and honoraria for lectures, advisory board participation or consulting from Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck & Co., Northwest Biotherapeutics, Novocure, Pfizer, Roche and Teva. D.M.F., G.B.F., C.B., Z.L.G., J.A.K., A.V., S.G.W. and S.J. declare no competing interests.